10.06.2015 • News

Chemours Spin-off from DuPont Finalized for July 1

DuPont’s board of directors has given final approval for the spin-off of the US group’s performance chemical business into a new standalone company known as The Chemours Company with effect from July 1, 2015.
In the spin-off, DuPont’s shareholders will receive one share of Chemours common stock for every five shares they hold in DuPont.
Trading of the shares is expected to begin on or about June 19 under the symbol “CC WI” on the New York Stock Exchange and continue through June 30.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read